NR1H4 and ovarian carcinoma: Interestingly, a Phase I pharmacokinetic trial and correlative in vitro Phase II tumor kinetic study of apomine, a FXR agonist, demonstrated inhibition of tumor growth from patients with ovarian cancer [21].